ESTRO 36 Abstract Book

S382 ESTRO 36 _______________________________________________________________________________________________

for items # 9, 17, 20, 22, and 26 (Figure 1). Finally, the predictive power of the 10 IBDQ-B items with respect to the acute worsening of the Bowel domain was investigated by means of ROC analyses, setting the 25 th percentile of the Δ with respect to baseline (-1.10, Table 1) as end- point. The IBDQ items # 1, 5, 13, 20 and 24 showed the highest discriminative power (AUC >80%) in detecting patients with acute IBDQ-B worsening.

higher Gleason Score(>7), TNM stage(>T3, N1, M1) and risk level than non-carriers.

Conclusion Acute, patient-reported, IT from IM-WPRT is mild, but some symptoms seem to persist one year after RT end. Five out of ten questions of IBDQ-B were shown to be more efficient in discriminating patients with larger acute worsening of IBDQ-B. PO-0728 BRCA2 mutation predicts poor survival in prostate cancer: A compelling evidence from 8,988 patients. M. Cui 1 , X.S. Gao 1 , X. Gu 1 , C. Peng 1 , X. Li 1 , M. Ma 1 1 Peking University First Hospital, Department of Radiation Oncology, Beijing, China Purpose or Objective To focus on clinicopathological characteristics and prognosis in men with prostate cancer (PCa) with Breast Cancer 2 (BRCA2) mutation and offer some convincing evidence for adding BRCA2 mutation as an early screening biomarker into NCCN and EAU guidelines. Material and Methods We searched relevant articles from PubMed, Embase, Web of Science and the Cochrane Library databases to evaluate the overall survival (OS) and cancer-specific survival (CSS) difference between BRCA2 mutation and non-carriers in patients with prostate cancer. This meta-analysis was performed following the (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) PRISMA Statement guidelines strictly. Results We totally incorporated 525 BRCA2 mutations versus 8,463 non-carriers from 10 studies in our meta-analysis. The results showed that BRCA2 mutation carriers was correlated with worse CSS and OS than non-carriers, with pooled Hazard Ratios (HRs) of 2.79 [95% confidence interval (CI): 2.04-3.81, P<0.001] and 2.21 (95%CI: 1.61- 3.02, P<0.001) respectively. The results also demonstrated that BRCA2 mutation carriers also harboring

Conclusion Our meta-analysis showed that BRCA2 mutation predicted poor survival outcomes in patients with PCa. Therefore, BRCA2 mutation as a helpful clinical prognostic factor could stratify the high risk patients and provide clinical strategies for more effective targeted treatments. PO-0729 Normal Tissue Complication Probability for late urinary toxicities after RT for prostate cancer F. Palorini 1 , A. Cicchetti 1 , T. Rancati 1 , C. Cozzarini 2 , B. Avuzzi 3 , C. Degli Esposti 4 , P. Franco 5 , E. Garibaldi 6 , G. Girelli 7 , C. Iotti 8 , V. Vavassori 9 , R. Valdagni 10 , C. Fiorino 11 1 Fondazione IRCCS Istituto Nazionale dei Tumori, Prostate Cancer Program, Milan, Italy 2 San Raffaele Scientific Institute, Radiotherapy, Milan, Italy 3 Fondazione IRCCS Istituto Nazionale dei Tumori, Radiation Oncology 1, Milan, Italy 4 Ospedale Bellaria, Radiotherapy, Bologna, Italy 5 Ospedale Regionale U. Parini-AUSL Valle d’Aosta, Radiotherapy, Aosta, Italy 6 Istituto di Candiolo – Fondazione del Piemonte per l’Oncologia IRCCS, Radiotherapy, Candiolo, Italy 7 Ospedale ASL9, Radiotherapy, Ivrea, Italy 8 Arcispedale S. M. Nuova – IRCCS, Radiotherapy, Reggio Emilia, Italy 9 Cliniche Gavazzeni-Humanitas, Radiotherapy, Bergamo, Italy 10 Fondazione IRCCS Istituto Nazionale dei Tumori, Prostate Cancer Program- Radiation Oncology 1, Milan, Italy